Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
about
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitisVedolizumab for induction and maintenance of remission in ulcerative colitisHistologic scoring indices for evaluation of disease activity in ulcerative colitisInterventions for induction of mucosal healing in ulcerative colitisInterventions for maintenance of mucosal healing in ulcerative colitisHumanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitisTacrolimus (FK506) for induction of remission in refractory ulcerative colitisCCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flowStructural specializations of α(4)β(7), an integrin that mediates rolling adhesionVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseReversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitisSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabVedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel diseaseReview of vedolizumab for the treatment of ulcerative colitisIntegrin-based therapeutics: biological basis, clinical use and new drugsOptimal management of steroid-dependent ulcerative colitisDiagnostic imaging advances in murine models of colitis.Promising biological therapies for ulcerative colitis: A review of the literatureInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsVedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's diseasePatient considerations in the management of ulcerative colitis - role of vedolizumabGenetic update on inflammatory factors in ulcerative colitis: Review of the current literatureShining a light on intestinal trafficReview article: anti-adhesion therapies for inflammatory bowel diseaseInflammatory pathways of importance for management of inflammatory bowel diseaseVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitisDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabEfficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysisIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CASummarizing historical information on controls in clinical trialsHistologic scoring indices for evaluation of disease activity in ulcerative colitis.The safety of vedolizumab for the treatment of ulcerative colitis.Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.Leukocyte adhesion molecules in animal models of inflammatory bowel diseaseCritical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis.Preliminary in vivo efficacy studies of a recombinant rhesus anti-alpha(4)beta(7) monoclonal antibody.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
P2860
Q24187044-3C47B35F-4255-4CE5-B81C-56AA8CA31AA7Q24194423-71FF8B23-4588-478C-A056-BC486EB646F1Q24194674-0EB79F29-F705-44B4-BF1A-D63A5AD06AE8Q24200747-ACC218CF-E909-4E79-B85A-0E8640236E4CQ24200760-B0C7BEF7-3A0F-4606-8EDE-0A638C95159BQ24241123-80AF74CC-D3AB-4859-9D01-8154210FFFB7Q24242681-86CB7A15-DC51-4F3D-A540-FA743B8A9DA3Q24318873-3AAECF4D-7F09-4FA3-B30E-ECB68021EFC0Q24611768-AB3FEB6C-C5B6-49A0-AF5B-DF47EB5EFF78Q24630083-64C76501-9F2F-4C4D-8C80-C41E97A4E95BQ24812028-FB0F0743-2DD4-4BBB-8BBF-2FE17E991FDBQ26748626-27FE11EB-31FA-4397-9AFE-FB764481E128Q26750456-475DE62A-2273-4971-8E36-C35A067CC978Q26752768-EB7832F4-6096-471A-A1F7-7F5EC2B77146Q26768259-74D60CB7-9A20-4CDD-A731-8EDD910225D4Q26773026-2FBED970-0787-4851-A152-40AA2814FBD7Q26773203-278B107A-3073-40B7-9441-3790D9557F36Q26774583-CCB189D5-FFB3-44AE-A858-8DA496971475Q26776139-04512F00-9FD2-45DB-B764-1EA9F3E6411AQ26785537-E92C0EB9-C84D-4B1B-835F-9B9972366ABAQ26786018-F1A507BE-4619-475D-882C-15A3230F046DQ26796432-FAEC59F0-6DF2-49DA-9ED3-9262E004028FQ26852514-912BEC4B-867F-4699-80EC-2ED1FADFB4F1Q26863227-3CE07B5A-1276-41F3-AE9E-0ABFBC8588A0Q26999705-DB896C27-6366-4EF2-83A6-C20899E86549Q27005445-315D01CA-58D8-4CDF-85F9-500BD79826E1Q27021612-A8D4D182-3564-4891-9E93-96BD8E89BBAAQ28080984-C98F6CA7-F849-4D31-95C7-1B673F029596Q28083872-A1C336AD-342A-430F-906C-807CD4A41601Q28084236-F2F6FB88-1F34-48B0-AC99-263E431E5D26Q28660580-C63FCA72-56CE-4FB1-B71E-B69CCA65A967Q29397593-2326FE71-1FE1-41D6-BCF7-3CC7F23F05D1Q30234366-B1B3FD0E-2E19-4E49-AEAF-E7A0D67466F0Q30235363-743DBBFE-F4BB-444C-A10D-8134E080D4D0Q30248641-4F582493-AA09-4B0D-862C-5C77FF598A9CQ30300234-79B72CEA-EBA1-4CF7-859C-8DAEE782A0C8Q30437758-79AAC2DC-CFD5-4E12-B1AE-C5C486FF1FE9Q30439952-B15B90F9-AB0B-4978-A193-B508E9403F73Q30491140-ECB70D7E-184C-4BFD-AB94-F0248416AE2CQ30902172-04167793-5894-47CF-B468-6100AB619A04
P2860
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@en
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@nl
type
label
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@en
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@nl
prefLabel
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@en
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@nl
P2093
P356
P1476
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
@en
P2093
A Hillary Steinhart
Albert Cohen
Gordon R Greenberg
Irving H Fox
John W D McDonald
Margaret K Vandervoort
Pierre Paré
Rasha A Aguzzi
Rejean Dubé
P304
P356
10.1056/NEJMOA042982
P407
P577
2005-06-01T00:00:00Z